Pay in 4 interest-free payments of $6.07 Learn more
Ships within 48 hours · Estimated delivery Jul 31 - Aug 5
Glucagon-like peptide-1 receptor agonists (GLP-1RAs) have transformed the therapeutic landscape of type 2 diabetes (T2D) and obesity by offering substantial weight loss and cardiometabolic protection
Reviewers consistently note improvements in focus, mental clarity, and productivity, particularly in academic and professional settings
Survodutide (BI 456906), developed by Boehringer Ingelheim and Zealand Pharma, has completed Phase 2 trials for both obesity (up to 18.7% weight loss at 46 weeks) and MASH (62% MASH resolution), earning FDA Breakthrough Therapy Designation for MASH
But it lacks what real GLP-1 clinics provide: medical oversight, proven medications, and structured care
US$ 23.34
US$ 25.53
US$ 20.33
US$ 22.02
US$ 27.70
US$ 28.12
US$ 28.74
US$ 20.86
